List of Excipients in API idelalisib
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing idelalisib
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Gilead Sciences Inc | ZYDELIG | idelalisib | 61958-1701 | ALUMINUM OXIDE | 2033-09-02 |
| Gilead Sciences Inc | ZYDELIG | idelalisib | 61958-1701 | CELLULOSE, MICROCRYSTALLINE | 2033-09-02 |
| Gilead Sciences Inc | ZYDELIG | idelalisib | 61958-1701 | CROSCARMELLOSE SODIUM | 2033-09-02 |
| Gilead Sciences Inc | ZYDELIG | idelalisib | 61958-1701 | FD&C YELLOW NO. 6 | 2033-09-02 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for idelalisib
Excipient focus: ALUMINUM OXIDE
idelalisib drug variants containing ALUMINUM OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | idelalisib | 61958-1701 |
| >Company | >Ingredient | >NDC |
idelalisib drug variants not containing ALUMINUM OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CELLULOSE, MICROCRYSTALLINE
idelalisib drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | idelalisib | 61958-1701 |
| >Company | >Ingredient | >NDC |
idelalisib drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
idelalisib drug variants containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | idelalisib | 61958-1701 |
| >Company | >Ingredient | >NDC |
idelalisib drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FD&C YELLOW NO. 6
idelalisib drug variants containing FD&C YELLOW NO. 6
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | idelalisib | 61958-1701 |
| >Company | >Ingredient | >NDC |
idelalisib drug variants not containing FD&C YELLOW NO. 6
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYDROXYPROPYL CELLULOSE
idelalisib drug variants containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | idelalisib | 61958-1701 |
| >Company | >Ingredient | >NDC |
idelalisib drug variants not containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
idelalisib drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | idelalisib | 61958-1701 |
| >Company | >Ingredient | >NDC |
idelalisib drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL
idelalisib drug variants containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | idelalisib | 61958-1701 |
| >Company | >Ingredient | >NDC |
idelalisib drug variants not containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYVINYL ALCOHOL
idelalisib drug variants containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | idelalisib | 61958-1701 |
| >Company | >Ingredient | >NDC |
idelalisib drug variants not containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM STARCH GLYCOLATE TYPE A POTATO
idelalisib drug variants containing SODIUM STARCH GLYCOLATE TYPE A POTATO
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | idelalisib | 61958-1701 |
| >Company | >Ingredient | >NDC |
idelalisib drug variants not containing SODIUM STARCH GLYCOLATE TYPE A POTATO
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
idelalisib drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | idelalisib | 61958-1701 |
| >Company | >Ingredient | >NDC |
idelalisib drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
idelalisib drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | idelalisib | 61958-1701 |
| >Company | >Ingredient | >NDC |
idelalisib drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch